Molecular Mimicry at the Gut–Immune Interface: A Mechanistic Link to Type 1 Diabetes
Immunology · 2026-04 · 177 (4) · 701-712
DOI: 10.1111/imm.70091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 29.12.2025. Verfasst von Sihan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Medicine, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Molecular Mimicry, Gastrointestinal Microbiome, Insulin-Secreting Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 116 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes (T1D) arises from T cell–mediated destruction of pancreatic β‐cells. However, genetic susceptibility alone cannot account for the increasing incidence and earlier onset of T1D, suggesting a substantial contribution from environmental factors, particularly the gut microbiota. This review synthesises recent human, multiomics and experimental evidence linking gut microbiota dysbiosis and microbial metabolites to β‐cell autoimmunity. We focus on two converging mechanisms: (1) metabolite‐driven disruption of intestinal barrier integrity and immune regulation, and (2) molecular mimicry between microbial peptides and islet autoantigens that activate autoreactive T cells. Across human cohorts and animal models, T1D‐associated dysbiosis features reduced short‐chain fatty acid (SCFA)‐producing bacteria (e.g., Faecalibacterium, Roseburia) and increased pro‐inflammatory taxa (e.g., Bacteroides, Streptococcus spp.). SCFA deficiency compromises Treg induction and gut barrier stability, facilitating antigen translocation. Several gut‐derived peptides, such as the Parabacteroides distasonis hprt4–18 peptide, share sequence homology with insulin and other islet antigens, activate insulin‐reactive T cells and accelerate diabetes in NOD mice, supporting a role for molecular mimicry. Interventional approaches including FMT, probiotics and prebiotics show promise but remain heterogeneous; their efficacy is highly strain‐, timing‐ and context‐dependent and translation from animal studies to humans is still limited. Therapeutically targeting the gut–islet axis, through modulation of microbiota, microbial metabolites or cross‐reactive antigens, offers potential for disease prevention or adjunctive treatment. We highlight emerging biomarkers, including MAIT‐cell phenotypes, antimicrobial peptide reactivity and microbiome‐derived functional signatures, and emphasise the need for stratified clinical trial designs based on age, genotype and baseline microbiota composition to address current variability. The microbiota–metabolite–molecular mimicry axis provides a coherent mechanistic framework linking gut dysbiosis to T1D pathogenesis. Advancing these insights into clinical application will require rigorous, genotype‐stratified human studies and standardised, transparent methodological approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Medical Microbiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.
ORCID-Profile: Sihan Chen, Shuiping Liu
Zitieren
APA
Chen, S., Luo, Y., Wei, G., & Liu, S. (2026). Molecular Mimicry at the Gut–Immune Interface: A Mechanistic Link to Type 1 Diabetes. Immunology, 177(4), 701-712. https://doi.org/10.1111/imm.70091
Vancouver
Chen S, Luo Y, Wei G, Liu S. Molecular Mimicry at the Gut–Immune Interface: A Mechanistic Link to Type 1 Diabetes. Immunology. 2026;177(4):701-712. doi:10.1111/imm.70091
BibTeX
@article{Chen2026,
author = {Chen, Sihan and Luo, Yixin and Wei, Gaoyang and Liu, Shuiping},
title = {Molecular Mimicry at the Gut–Immune Interface: A Mechanistic Link to Type 1 Diabetes},
journal = {Immunology},
year = {2026},
volume = {177},
number = {4},
pages = {701--712},
doi = {10.1111/imm.70091}
}
EUVIMED